Teva Canada Announces the Launch of <C>ACT Methylphenidate ER® Tablets, a Generic Version of <C>Concerta® for the Treatment of ADHD

- Currently available in Canada -

TORONTO, March 22, 2018 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for ^CACT Methylphenidate ER® tablets, the generic version of ^CConcerta® (methylphenidate hydrochloride). This once-daily extended release medication is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: Children (6 – 12 years of age); Adolescents (13 – 18 years of age); and Adults (>18 years of age).

ACT Methylphenidate ER® (CNW Group/Teva Canada Limited)

Methylphenidate extended release tablets (brand: ^CConcerta®) had annual sales of approximately $175 million in Canada, based on IQVIA sales data as of January 2018.  ^CACT Methylphenidate ER® is available immediately to pharmacies across Canada.

"We've heard from healthcare providers, ADHD patients and their parents about the need for an affordable alternative to ^CConcerta® that works in the same way and at the same time," said David Boughner, Senior Director Commercial Management for Teva Canada Limited. "We're pleased to offer patients ^CACT Methylphenidate ER® as a bioequivalent modified release product that allows for a biphasic drug release profile after oral administration.  In addition, the pharmacokinetic parameters mimic the concentration-time release profile of ^CConcerta®."

Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder characterized by inattention, disorganization and/or hyperactivity or impulsivity. ADHD is the most common neurodevelopmental disorder in children, affecting about one in 20 children and is more common in boys than girls. ADHD persists into adulthood for at least 60% of children with the disorder. About 4.5% of adults have ADHD, but most have not been properly diagnosed or treated.  ADHD is highly treatable and people with ADHD can function well if they receive effective treatments and interventions.^[i]

Helping People Live Better Days

At Teva, we help to improve the health of 200 million people every day by providing innovative treatments and access to the world's largest medicine cabinet of generic and specialty medicines. This gives us a unique perspective on health. Understanding the many ways health impacts people's lives inspires us to discover new possibilities to bring medicines and more, enabling patients and caregivers to live better days.

About Teva Canada Limited

Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with sales of more than $1 billion^[ii] in 2017 and over 249,000^[iii] prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada Limited specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,000 individuals, markets more than 400^[iv] products in 1,700 SKUs in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.

_________________________
ⁱ Portico – Canada's Mental Health and Addiction Network. Attention-deficit/hyperactivity disorder: Overview  https://www.porticonetwork.ca/treatments/disorders-qr/adhd/adhd-orientation – Accessed March 2018
https://www.porticonetwork.ca/web/psychiatry-primary-care/clinical-situations/adhd – Accessed March 2018
ⁱⁱ Source: IQVIA CDH & Compuscript MAT January 2018
ⁱⁱⁱ Source: IQVIA CDH & Compuscript MAT January 2018
^iv Source: IQVIA CDH & Compuscript MAT January 2018

SOURCE Teva Canada Limited

IR Contacts: United States: Kevin C. Mannix, [phone]; Ran Meir, [phone]; Israel: Tomer Amitai, 972 (3) 926 7656; PR Contacts: United States: Elizabeth DeLuca, [phone]; Israel: Yonatan Beker, 972 (54) 888 5898